## SANTA CRUZ BIOTECHNOLOGY, INC.

# DcR2 siRNA (h): sc-35185



#### BACKGROUND

Tumor necrosis factor (TNF) is a pleiotropic cytokine whose function is mediated by two distinct cell surface receptors, designated TNF-R1 and TNF-R2, which are expressed on most cell types. TNF function is primarily mediated through TNF-R1 signaling. Both receptors belong to the growing TNF receptor superfamily which includes FAS antigen and CD40. TNF-R1 contains a cytoplasmic motif, termed the "death domain", that has been found to be necessary for the transduction of the apoptotic signal. The death domain is also found in several other receptors, including FAS, DR2 (or TRUNDD), DR3 (death receptor 3), DR4, DR5 and DR6. TRUNDD, DR4 and DR5 are receptors for the apoptosis-inducing cytokine TRAIL. Non-death domain-containing receptors, designated decoy receptor 1 (DcR1) or TRID, DcR2 and DcR3, associate with specific ligands and may play a role in cellular resistance to apoptotic stimuli.

### CHROMOSOMAL LOCATION

Genetic locus: TNFRSF10D (human) mapping to 8p21.3.

### PRODUCT

DcR2 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see DcR2 shRNA Plasmid (h): sc-35185-SH and DcR2 shRNA (h) Lentiviral Particles: sc-35185-V as alternate gene silencing products.

For independent verification of DcR2 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-35185A, sc-35185B and sc-35185C.

#### STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNAse-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

#### APPLICATIONS

DcR2 siRNA (h) is recommended for the inhibition of DcR2 expression in human cells.

#### SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10  $\mu$ M in 66  $\mu$ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

#### **GENE EXPRESSION MONITORING**

DcR2 (B-P30): sc-65310 is recommended as a control antibody for monitoring of DcR2 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

### **RT-PCR REAGENTS**

Semi-quantitative RT-PCR may be performed to monitor DcR2 gene expression knockdown using RT-PCR Primer: DcR2 (h)-PR: sc-35185-PR (20  $\mu$ l, 506 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

#### SELECT PRODUCT CITATIONS

- Sanlioglu, A.D., et al. 2005. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 5: 54.
- Terzioglu, E., et al. 2007. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology 46: 783-789.
- Aydin, C., et al. 2007. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosisinducing ligand resistance in lung cancer cells. Hum. Gene Ther. 18: 39-50.
- Sanlioglu, A.D., et al. 2007. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down *in vitro* tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther. 14: 976-984.
- Jin, W., et al. 2020. Ischemic preconditioning upregulates decoy receptors to protect SH-SY5Y cells from OGD induced cellular damage by inhibiting TRAIL pathway and agitating PI3K/Akt pathway. Mol. Neurobiol. 57: 3658-3670.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.